Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.

Description

By leveraging visual analytics through TIBCO Spotfire®, PerkinElmer Signals Translational offers a comprehensive suite of tools designed to harmonize, manage, search, aggregate, and analyze extensive datasets consistently for translational research, all while ensuring scalability. This platform, driven by TIBCO Spotfire®, supports precision medicine initiatives by providing an unparalleled solution for biomarker discovery and patient stratification. The Linear Mixed Effect App (LME) within Signals Translational empowers researchers to evaluate the influence of various factors on specific phenotypes, allowing for adjustments related to random variables during analysis. Furthermore, it enables the identification of genes significantly affecting cancer stage progression, irrespective of patient origins. Notably, the LME models excel at addressing issues such as missing values and outliers, making them a robust choice for discovering potential biomarkers. Consequently, the integration of these advanced analytics tools enhances the efficacy of translational research in identifying key biomarkers that can lead to more personalized treatment approaches.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

Signals Research Suite

Integrations

Signals Research Suite

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

BenevolentAI

Founded

2013

Country

Luxembourg

Website

www.benevolent.com

Vendor Details

Company Name

PerkinElmer

Founded

1937

Country

United States

Website

perkinelmerinformatics.com/products/clinical-translational/signals-translational/

Product Features

Alternatives

Alternatives

Signals Inventa Reviews

Signals Inventa

PerkinElmer Informatics
TIBCO Platform Reviews

TIBCO Platform

Cloud Software Group